Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pannier, B.
Right arrow Articles by London, G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results

B. Pannier, A.P. Guérin, S.J. Marchias and G.M. London1

Service d'Hémodialyse, Hôpital F.H. Manhès, Fleury-Mérogis, France

1 Dr Gérard M. London, Service d'Hémodialyse, Hôpital F.H. Manhes, 8 Grande Rue, 91712, Fleury-Mérogis, France.

Abstract

Epidemiological and clinical studies have shown that cardiovascular disease is a major contributory factor to high morbidity and mortality in patients with end-stage renal disease (ESRD). This exvess mortality is related principally to left ventricular hypertrophy (LVH) and increased arterial stiffness and their interaction. Recent findings have indicated that aortic pulse wave velocity (PWV), a marker of aortic stiffness, is a strong independent predictor or cardiovascular and all-cause mortality in patients with ESRD who are on haemodialysis. Furthermore, it was shown in a therapeutic trial that lack of aortic PWV attenuation despite significant drug-induced reduction in blood pressure was a significant predictor of cardiovascular death in patients with ESRD. Moreover, the absence of PWV attenuation was associated with lack of regression of LVH, which by itself was associated with poor outcome. Controlled trials have also shown that angiotensin-converting enzyme inhibitors are the most efficient drugs for regression of LVH. Moreover, independently of its effects on left ventricular mass and blood perssure, the prescription of the ACE inhibitor perindopril, whether in combination or alone, had a strong and independent beneficial impact on all-cause and cardiovascular survival. After adjustment for all confounding factors, the risk ratio for perindorpil use was 0.19 for all-cause mortality and 0.18 for cardiovascular mortality. These results indicate that, in patients with ESRD, improvement in arterial stiffness and regression of LVH are associated with a better prognosis and that the use of the ACE inhibitor perindopril has a favourable effect on survival that is independent of haemodynamic alterations.

Key Words: Arterial stiffness • Aorta • Cardiovascular risk • End-stage renal disease • Prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.